2 research outputs found
Die FrĂŒh- und SpĂ€tergebnisse nach Assist-Device Implantation im SĂ€uglings- und Kindesalter am UniversitaÌtsklinikum der LMU-MĂŒnchen
Motor outcome, executive functioning, and healthârelated quality of life of children, adolescents, and young adults after ventricular assist device and heart transplantation
Objective
The aim of the current study is to measure longâterm executive function, motor outcome, and QoL in children, adolescents, and young adults after VAD and Htx.
Methods
Patients were examined during routine followâup. Investigation tools were used as follows: Examination for MND of motor outcomes, EpitrackÂź for attention and executive functioning, and Kidscreenâ52 and EQâ5Dâ5L questionnaires for QoL. Additional data were retrospectively obtained by an analysis of patient medical records.
Results
Out of 145 heart transplant recipients at the department of pediatric cardiology of the University Hospital Munich, 39 were implanted with a VAD between 1992 and 2016. Seventeen (43.6%) patients died before or after Htx; 22 (56.4%) patients were included in our study. Mean age at transplant was 9.52 years (range: 0.58â24.39 years, median 9), and the mean followâup time after Htx was 6.18 years (range: 0.05â14.60 years, median 5.82). MND examination could be performed in 13 patients (normal MND: n = 11, simple MND: n = 1, complex MND: n = 1). Executive functioning was tested in 15 patients. Two (13.3%) patients had good results, six (40%) average results, three (20%) borderline results, and four (26.7%) impaired results. QoL (Kidscreen n = 7, EQâ5Dâ5L n = 8) was similar to a healthy German population.
Conclusion
Motor outcome, executive functioning and QoL in survivors of VAD bridging therapy and Htx can be good, though underlying diseases and therapies are associated with a high risk of cerebral ischemic or hemorrhagic complications